Ratings by Guggenheim (Brad Canino )
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/28/2026 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2026 | AN2 Therapeutics | ANTX | New Coverage | Buy (N/A) |
4.67 (5.33) |
14.13% | Details | |
| 6/10/2026 | Nuvalent | NUVL | Downgrade | Neutral (Buy) |
123.25 (123.96) |
0.58% | Details | |
| 6/3/2026 | Celcuity Inc | CELC | Maintain | Buy (Buy) |
|
Details | ||
| 5/26/2026 | Relay Therapeutics | RLAY | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Buy (N/A) |
23.09 (26.27) |
13.77% | Details | |
| 5/8/2026 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2026 | Celcuity Inc | CELC | Maintain | Buy (N/A) |
|
Details | ||
| 4/14/2026 | Tyra Biosciences | TYRA | New Coverage | Buy (N/A) |
35.62 (33.06) |
-7.19% | Details | |
| 3/17/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2026 | Relay Therapeutics | RLAY | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2026 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2026 | Celcuity Inc | CELC | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2026 | Galecto | GLTO | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2026 | Cullinan Oncology Inc. | CGEM | New Coverage | Buy (N/A) |
11.92 (17.52) |
46.98% | Details | |
| 1/21/2026 | Crescent Biopharma Inc | CBIO | New Coverage | Buy (N/A) |
13.98 (15.02) |
7.44% | Details | |
| 12/8/2025 | Galecto | GLTO | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2025 | Galecto | GLTO | New Coverage | Buy (N/A) |
17.39 (28.69) |
64.98% | Details | |
| 11/20/2025 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2025 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
61.44 (107.01) |
74.17% | Details | |
| 10/8/2025 | CG Oncology | CGON | New Coverage | Buy (N/A) |
38.13 (73.03) |
91.53% | Details | |
| 10/8/2025 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
11.06 (11.82) |
6.87% | Details | |
| 9/22/2025 | Celcuity Inc | CELC | New Coverage | Buy (N/A) |
55.03 (87.64) |
59.26% | Details | |
| 9/4/2025 | ORIC Pharmaceuticals | ORIC | New Coverage | Buy (N/A) |
10.38 (11.64) |
12.14% | Details | |
| 9/4/2025 | Summit Therapeutics plc | SMMT | New Coverage | Buy (N/A) |
23.84 (13.44) |
-43.62% | Details | |
| 9/4/2025 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
22.86 (15.58) |
-31.85% | Details | |
| 9/4/2025 | Relay Therapeutics | RLAY | New Coverage | Buy (N/A) |
3.66 (19.45) |
431.42% | Details | |
| 9/4/2025 | C4 Therapeutics | CCCC | New Coverage | Buy (N/A) |
2.51 (3.66) |
45.82% | Details |
